Summary
Interleukin 6 (IL-6) is a major growth factor for tumor plasma cells involved in human multiple myeloma (MM). In particular, human myeloma cell lines (HMCL), whose growth is completely dependent on addition of exogenous IL-6, can be obtained reproducibly from every patient with terminal disease. Four cytokines, ciliary neurotropic factor (CNTF), IL-11, leukemia inhibitory factor (LIF), and oncostatin M (OM), use the same transducer chain (signal transducer gpD0) as IL-6 and share numerous biological activities with this IL. We found that these four cytokines stimulated proliferation and supported the long-term growth of two out of four IL-6-dependent HMCL obtained in our laboratory. Half-maximal proliferation was obtained with cytokine concentrations ranging from 0.4 to 1.2 ng/ml for IL-11, LIF, and OM. CNTF worked at high concentrations only (90 ng/ml), but addition of soluble CNTF receptor increased sensitivity to CNTF 30-fold. The growth-promoting effect of these four cytokines was abrogated by antigp130 antibodies, contrary to results for anti-IL-6 receptor or anti-IL-6 antibodies. No detectable changes in the morphology and phenotype were found when myeloma cells were cultured with one of these four cytokines instead of IL-6. Concordant with their IL-6-dependent growth, the four HMCL expressed membrane IL-6R and gpD0 detected by FACS | analysis. LIF-binding chain gene (LIFR) was expressed only in the two HMCL responsive to LIF and OM.
M ultiple myeloma (MM) is a B cell neoplasia affecting the late stages of B cell differentiation (plasma cells).
We and others have shown that IL-6 is a major growth factor for tumor plasma cells in vitro and that treatments with anti-IL-6 antibodies could result in blockage of tumor proliferation in vivo (1) (2) (3) . In addition, we have been able to obtain human myeloma cell lines (HMCL) reproducibly, whose growth is completely dependent on addition of exogenous IL-6 (4 and Zhang, X.-G., unpublished results).
As IL-11, leukemia inhibitory factor (LIF), and oncostatin M (OM) share similar biological effects with IL-6 as inducers of acute-phase proteins, stimulators of thrombopoiesis, and as competence factor for hematopoietic cells (5-8), we investigated whether they could support the growth of human myeloma cells. The overlapping biological activities of these cytokines is to be explained by their use of multicomponent receptors, including a common transducer gp130 unit (9-13). gp130 was first identified as an IL-6 signal transducer (14) . IL-6 binds to its specific receptor (IL-6R), with a low affinity of about 10-9 M (15). IL-6R has no transducing activity, but the complex formed by IL-6 and IL-6R binds to gp130 (14) , resulting in the formation of a high aff~ty IL-6 receptor, dimerization, phosphorylation, and activation of the transducer gp130 (14, 16) . LIF was initially shown to bind with low affinity to a receptor subunit (LIFR~) related to gp130 (17) . The transducer gpl30 was subsequently found to convert LIFI~ into a high affinity binding site for OM as well as LIF (9) . Finally, the IL-11 receptor is presently unidentified but was recently shown to include the transducer gp130 (12) . Another cytokine, ciliary neurotropic factor (CNTF), also uses the transducer gp130. It has a more restricted spectrum of biological activity than IL-6, LIF, or OM, possibly because of restricted expression of the CNTF binding protein (termed CNTFKot) found mainly in neuronal tissues (18) . CNTFKc~ binds CNTF with low affinity (18) . This receptor has no cytoplasmic tail and is linked to the cell membrane through glycosyl phosphatidylinositol. Addition of CNTFKot to the LIFKB/gp130 complex has been shown to convert a functional LIF or OM receptor into a functional CNTF receptor (19) . CNTFKot and IL-6K share strong homologies (15, 18) , and a unique feature is that their soluble forms have an agonist activity, whereas all known soluble cytokine receptors have an antagonist activity. When bound to their respective ligands, they can activate the transducer complex (14, 20, 21) .
As noted above, the common use of the IL-6 signal transducer gp130 by CNTF, IL-11, LIF, and OM may account for their overlapping biological effects with IL-6. An immediate consequence could be that these four cytokines, like IL-6, are also involved in numerous diseases: infectious, autoimmune, and cancer diseases, and particularly human MM (6) .
We report here that cytokines CNTF, IL-11, LIF, and OM are potent growth factors for human myeloma ceils. Their myeloma cell growth factor activity is inhibited by anti-g'pl30 antibodies unlike anti-IL-6 or anti-IL-6R antibodies.
Materials and Methods

HMCL.
The four HMCL (XG-1, XG-2, XG-4, XG-6) were obtained by culturing freshly explanted mydoma cells from patients with terminal disease with a combination of II.-6 and GM-CSF (4 and Zhang, X.-G., unpublished results). These HMCL have a plasma cell phenotype and the same immunoglobulin gene rearrangements as patients' tumor cells, and their growth is completely dependent on addition of IL-6. Their characteristics are reported elsewhere (4 and Zhang, X.-G., manuscript in preparation). HMCL were free of mycoplasma contamination and were routinely cultured in RPMI 1640 supplemented with 5% FCS and 1 ng/ml of recombinant (r)ID6.
HMCL Proliferation Assay. To investigate their responsiveness
to various cytokines, XG ceils were washed once with culture medium, incubated for 5 h at 370C in culture medium alone, and washed again twice. Cells were then cultured at various concentrations in 96-well fiat-bottomed microplates for 2 or 5 d with either culture medium alone or graded concentrations of various cytokines. BE-8 anti-Ib6, BIL-6 anti-II~6P,, and GPX7 and GPZ35 anti-gp 130 mAbs (22) were added at the beginning of the cultures (final concentration 10/xg/ml). A mouse purified IgG1 (Bb5) was used as control antibody. 0.5/~Ci of tritiated thymidine (25 Ci/mM; CEA, Saclay, France) was added for the last 8 h of culture, and tritiated thymidine incorporation was determined as reported elsewhere (23) .
Phenotyl~ Analysis. The phenotype of the XG lines was studied using mAbs to various human antigens and an anti-mouse Ig antibody coupled with fluorescein isothiocyanate (Immunotech, Marseilles, France). Fluorescence analysis was performed with a flow cytometer (ATC 3000/KCA 3000; Bruker, Wissembourg, France). Antibodies to CD19, CD21, CD23, CD28, CD32, CD38, CD40, and CD56 antigens were purchased from Immunotech. The characteristics of MT18 anti-IL-6K and GPX7 and GPZ35 anti-gpl30 were previously reported (22, 24) . Cytoplasmic immunoglobulin heavy and light chains were detected by specific antibodies coupled with fluorescein (Kallestadt, Austin, TX).
Detection of LIFRfl Expression by PCR. Aliquots of XG cells
(50 x 10 ~ cells), cultured with 1 ng/nd of rIL-6, were harvested during the exponential growth phase and frozen in nitrogen for RNA studies, cDNA was synthesized from 1/~g total KNA from each cell line. 35 cycles of PCR (45 s at 94~ 45 s at 650C, 90 s at 72~ followed by 3-min extension at 720C were carried out using primers corresponding to nucleotides 155-175 and 1501-1525 of LIFt~ sequence (17) . This gives a 1.37-kb product. 15 ~1 of each 25-/~1 PCR reaction were electrophoresed on 1.5% agarose gel in TAE buffer and transferred onto Hybond filters (Amersham, Les Ulis, France). Filters were hybridized with a LIFR~ cDNA probe labeled with [32P]dCTP by a random priming method (Boehringer Mannheim, Meylan, France) and were exposed to Kodak XAR5 films at -70~ for 2 h.
Immunoglobulin Production. Immunoglobulin production was measured in culture supernatants of XG cells using an ELISA and anti-human heavy and light immunoglobulin chains purchased from Immunotech. Supernatants were prepared by culturing 5 x 105 cells/ml for 2 d with the various cytokines.
Reagents. Figs. 1 and 2 . XG-1, XG-2, XG-4, and XG-6 HMCL could not proliferate and grow without addition of an exogenous cytokine, and high proliferation was induced by rlL-6. The four cytokines (rCNTF, rlL-11, rLIF, and tOM) also induced significant proliferation of XG-4 and XG-6 myeloma cells.
Results
CNTF, IL-I1, LIF, and OM Are Growth Factors for Human Myeloma Cells. Results are shown in
Proliferation of XG-1 and XG-2 ceils was supported by rlL-6 alone. Half-maximal proliferation of XG-4 and XG-6 myeloma ceils was induced by 100 and 70 pg/ml of rlL-6, 800, and 1200 pg/ml of rlL-11, 324 and 470 pg/mt of rLIF, and 440 and 410 pg/ml of tOM, respectively. Only XG-4 cells were significantly stimulated by large concentrations of rCNTF (half-maximal proliferation induced by 90 ng/ml of rCNTF). XG-6 cells were only marginally stimulated, and XG-1 and XG-2 cells were not stimulated by rCNTF (Fig. 1) .
rlL-11, rLIF, or rOM supported the long-term growth of XG-4 and XG-6 (>6 too), unlike XG-1 and XG-2 HMCL (Fig. 2) , making it possible to obtain XG-4 or XG-6 subclones whose growth was strictly dependent on addition of the initial cytokine. XG-4, but not XG-6 HMCL, could be grown with rCNTF alone (Fig. 2) 
DAYS OF CULTURE
No changes in the morphology, phenotype or immunoglobulin secretion of XG-4 and XG-6 myeloma cells were found when cultured for more than 4 wk with IL-11, LIF, or OM instead of IL-6 (results not shown).
Myeloma-Cell Growth Factor Activity of CNTF, IL-II, LIF,, and OM Was Mediated Through IL-6 Signaling gpl30 Trans-
duc~ Proliferation of XG-4 and XG-6 cells induced by rIL,6, rCNTF, rib11, rLIF, or rOM was completdy inhibited by anti-gp130 mAb (Fig. 3) . Anti-lL-6R or anti-IL-6 mAb completely inhibited rlL-6-induced proliferation and did not affect growth induced by rCNTF, rIL-11, rLIF, or rOM (Fig. 3) .
Soluble CNTFRc~ Potentiated the CNTF Res~nse of HMCL.
As noted above, rCNTF induced a proliferative response in XG-4 cells at high concentration only (half-maximal proliferation obtained with 90 ng/ml). Addition of soluble CNTFKc~ increased the sensitivity of XG-4 cells 30-fold, half-maximal proliferation being obtained with 3 ng/ml of rCNTF (Fig.  4) . Again, the potentiating effect of sCNTFKc~ was completely abrogated by anti-gp130 mAb (Fig. 4) .
Expression of LIFP, q8
Gene by XG Cells. The four HMCL expressed membrane IL-6K and the transducer gp130, which could be detected by a specific mAb and FACS | analysis (Becton Dickinson & Co., Mountain View, CA). LIFRB Figure 2 . Long-term growth of human myeloma cell lines stimulated by Ib6, CNTF, Ib11, LIE or OM. XG-4 or XG-6 cells were cultured at a cell concentration of 10 s cells/ml with either no exogenous cytokine, or 1 ng/ml of rlL-6, 300 ng/ml of rCNTF, 10 ng/ml of rlI~11, 10 ng/ml of rLIF, or 10 ng/ml of tOM. For each culture group, XG cells were diluted every 4 d at a cell concentration of 10 s cells/ml in fresh culture medium containing the initial cytokine concentration. Results are the cumulative numbers of cells generated in each culture group. Figure 3 . Growth factor activity of CNTF, IL-11, LIF, and OM is abrogated by anti-gp130 antibodies. XG-4 and XG-6 cells were cultured at a concentration of 105 cells/ml for 5 d with either no cytokine, 300 pg/ml of rIL-6, 300 ng/ml of rCNTF, 10 ng/ml of rlL-11, 10 ng/ml of rLIF, or 10 ng/ml of tOM. For each cytokine, culture groups containing either a control antibody, 10 rig/m1 of GPX7 and GtrZ35 anti-gp130 mAb, 10 #g/mi of BK-6 anti-lb6K mAb, or 10 #g/ml of B-E8 anti-IL-6 mAb were prepared. Proliferation was assayed by tritiated thymidine incorporation. Results are mean values determined on sextuplate culture wells.
mRNA was detected by PCR amplification in XG-4 and XG-6 ceils but not in XG-1 and XG-2 cells (Fig. 5 ).
D i s c u . i o n
We and others have shown that IL-6 is a major growth factor for the proliferation of tumor plasma cells in human Figure 5 . Detection of LIFR, fl gene expression in XG cells by PCR. cDNA was synthesized from 1/zg total R_NA from each XG cell line. 35 cycles of PCIL (45 s at 94~ 45 s at 60"C, and 90 s at 72"C) were carried out using primers corresponding to nudeotides 155-175 and 1501-1525 of LIFILfl sequence. The 1.37-kb product of PCR was electrophoresed in 1.5% agarose, transferred onto falters, and hybridized with a LIFR43 cDNA probe labeled with 321). multiple myeloma (1, 2) . In particular, for every patient with terminal disease, IL-6 enables human myeloma cell lines to be obtained whose proliferation is completely dependent on addition of exogenous IL-6 (4 and Zhang, X.-G., unpublished results).
In this work, we showed that IL-11, OM, and LIF were growth factors similar to IL-6 for two of the four H M C L studied. These cytokines allowed us to obtain subclones whose growth is completely dependent on addition of IL-11, LIF, or OM. The four H M C L expressed membrane IL-6R and the transducer l~p130 which could be detected by a specific mAb and FACS | analysis. The sensitivity to LIF or O M was found to correlate with the presence ofLIFRfl m R N A which was detected in XG-4 and XG-6 but not in XG-1 and XG-2 cells. It is likely that these two H M C L also express an IL-11-binding protein not presently identified.
XG-4 and XG-6 cells were stimulated only at high concentrations of C N T F (half-maximal proliferation induced by 90 ng/ml). This biological effect can be explained by a possible low affinity interaction of C N T F with the heterodimer . In one culture group, 10/~g/ml of the GPX7 and GtrZ35 anti-gpD0 mAb were added. Proliferation was assayed using tritiated thymidine incorporation.
Results are mean values determined on sextuphte culture wells.
LIFRB and gp130 in the absence of CNTFRot, as previously reported (20) . This was confirmed by the 30-fold increase in the sensitivity of myeloma cells to CNTF in the presence of soluble CNTFRcx. Soluble IL-6R can also potentiate the response of cells to IL-6 (14, 21) . Thus, soluble forms of these receptors bound to their ligand actually behave like cytokines that are able to activate their transducer complex. This concept is supported by the fact that IL-12 is a heterodimer composed of one chain homologous to IL-6 and another chain homologous to IL-6R (25) . Our previous finding that the presence of high concentration of soluble IL-6R in patients with MM is associated with poor prognosis might in part be explained by this concept (26) . Soluble forms of LIFRB and gp130 have also been found in the serum of mice or humans. These soluble forms have an antagonist activity (27, 28) .
Thus, we showed that mechanisms previously demonstrated with transfected cells are operational in freshly obtained tumor cell lines (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . In a recent study, Nishimoto et al. (29) demonstrated that LIF and OM are also growth factors for freshly explanted myeloma cells. In the case of multiple mydoma, we previously showed that IL-6 overproduction in vivo was associated with poor prognosis (30) and that treatment with anti-IL-6 antibodies could result in complete blockage of tumor proliferation in vivo (3). It is now essential to determine whether CNTF, IL-11, LIF, OM, sotuble IL-6R, or soluble CNTFRo~ is produced in tumor proliferation sites in patients with MM. In particular, it is important to find out whether resistance to therapy in patients treated with anti-IL-6 antibodies is associated with production of one of these cytokines in vivo (3) . The fact that the 5 cytokines using the same gp130 transducer are myeloma cell growth factors suggests that the concept of multiple myeloma as an IL-6-related disease should be extended to that of a gp130-dependent disease. Kaposi sarcoma, another IL-6-related disease, is also related to OM (31) . Thus, agents able to block the activation of gp130 without killing cells expressing it (i.e., almost every cell in the body) should be extremely useful for treatment of the numerous diseases initially considered to be IL-6 related.
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